Eli Lilly announced positive Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist, demonstrating significant weight loss and glycemic control improvements in adults with obesity and type 2 diabetes. The highest dose led to a 9.6% weight reduction over 72 weeks and appreciable A1C declines, with most patients achieving improved glycemic thresholds. All doses met primary and secondary endpoints, though discontinuation due to side effects was higher than placebo. Lilly aims to file for regulatory approval soon, competing in a growing oral GLP-1 market dominated by injectable therapies. Observers noted efficacy comparable to existing agents but raised tolerance concerns.